...
首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas.
【24h】

In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas.

机译:CTLA4抑制受体在人淋巴瘤的恶性和反应性细胞中的体内表达。

获取原文
获取原文并翻译 | 示例
           

摘要

The CTLA4 receptor is a CD28 homologue which induces inhibitory effect on activated T-cells. Peripheral T-cells proliferate spontaneously in CTLA4-deficient mice. These results led to an analysis of CTLA4 expression in human lymphomas (n = 82) including Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHLs), using immunohistochemistry. CTLA4 was present in neoplastic cells from most (10/11) T-cell malignancies, except for anaplastic and lymphoblastic subtypes (0/4). Malignant B-cells from rare (3/55) B-NHLs (all of follicular subtype) were also CTLA4-positive. Other B-NHLs (52/55) were negative in malignant B-cells and occasionally positive in T-cells. Reactive small lymphocytes, but not Reed-Sternberg cells, from all (12/12) HD cases were strongly CTLA4-positive. The CTLA4 ligands CD80 and CD86 were simultaneously expressed in most CTLA4-negative lymphoma cases. CTLA4 is thus expressed either in the reactive or in the malignant cell populations, depending on the lymphoma subtype. These results provide new insights leading towards therapeutic strategies based either on enhancement of anti-tumour immunity by CTLA4 blockade in reactive lymphocytes or on triggering of a CTLA4-mediated inhibitory pathway in lymphoma cells.
机译:CTLA4受体是CD28同源物,可诱导对活化T细胞的抑制作用。周围T细胞在CTLA4缺陷小鼠中自发增殖。这些结果导致使用免疫组织化学分析了人类淋巴瘤(n = 82)包括霍奇金病(HD)和非霍奇金淋巴瘤(NHL)中CTLA4的表达。 CTLA4存在于大多数(10/11)T细胞恶性肿瘤的赘生性细胞中,除间变性和淋巴母细胞亚型(0/4)外。罕见的(3/55)B-NHL(均为滤泡亚型)的恶性B细胞也CTLA4阳性。其他B-NHL(52/55)在恶性B细胞中阴性,在T细胞中偶发阳性。所有(12/12)HD病例中的反应性小淋巴细胞(而非Reed-Sternberg细胞)均为强CTLA4阳性。在大多数CTLA4阴性淋巴瘤病例中,CTLA4配体CD80和CD86同时表达。因此,根据淋巴瘤亚型,CTLA4在反应性或恶性细胞群体中表达。这些结果提供了新的见解,从而基于基于反应性淋巴细胞中CTLA4阻断的抗肿瘤免疫增强作用或触发了淋巴瘤细胞中CTLA4介导的抑制途径的触发,从而提出了治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号